- Home
- KZIA vs DSS Comparison
KZIA vs DSS Comparison
Compare KZIA & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | DSS |
|---|---|---|
| Founded | 1994 | 1984 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 9.1M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | KZIA | DSS |
|---|---|---|
| Price | $7.63 | $0.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 254.3K | 8.6K |
| Earning Date | 12-26-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,199,108.00 | ★ $22,046,000.00 |
| Revenue This Year | N/A | $14.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.53 |
| 52 Week Low | $2.86 | $0.72 |
| 52 Week High | $17.40 | $1.90 |
Technical Indicators
Market Signals| Indicator | KZIA | DSS |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 44.11 |
| Support Level | $6.65 | $0.92 |
| Resistance Level | $11.06 | $0.99 |
| Average True Range (ATR) | 2.08 | 0.04 |
| MACD | -0.59 | 0.00 |
| Stochastic Oscillator | 12.56 | 41.18 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.